

Resource Summary Report

Generated by [dkNET](#) on Sep 1, 2026

B16

RRID:CVCL_F936

Type: Cell Line

Proper Citation

RCB Cat# RCB1283, RRID:CVCL_F936

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_F936

Proper Citation: RCB Cat# RCB1283, RRID:CVCL_F936

Description: Cell line B16 is a Cancer cell line with a species of origin *Mus musculus* (Mouse)

Sex: Male

Disease: Mouse melanoma

Defining Citation: [PMID:1109790](#), [PMID:4981070](#), [PMID:5513504](#), [PMID:6498800](#)

Comments: Miscellaneous: This line seems to be the B78 line described in PubMed=4981070 which itself seems to be derived from the HFH-18 line that itself originate from a B16 melanoma.

Category: Cancer cell line

Organism: *Mus musculus* (Mouse)

Name: B16

Synonyms: B-16, B16 melanoma, B16 subline B78, B78

Cross References: CLO:CLO_0050752, EFO:EFO_0022766, CCRID:1101MOU-PUMC000215, CCRID:1101MOU-PUMC000324, CCRID:3101MOUTCM2, CCRID:5301MOU-KCB14029YJ, ChEMBL-Cells:ChEMBL3308454, ChEMBL-Targets:ChEMBL381, CLS:305154, JCRB:JCRB0202, KCB:KCB 2014029YJ, KCB:KCB 93030YJ, PubChem_Cell_line:CVCL_F936, RCB:RCB1283, TKG:TKG 0144, TOKU-E:3564, Wikidata:Q25112368

ID: CVCL_F936

Vendor: RCB

Catalog Number: RCB1283

Hierarchy: cvcl_gs32

Record Creation Time: 20220427T215231+0000

Record Last Update: 20260830T002302+0000

Ratings and Alerts

No rating or validation information has been found for B16.

No alerts have been found for B16.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 32 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Aobulikasimu N, et al. (2026) Galangin-loaded biomimetic dendritic cells membrane nanovaccine reprograms the ovarian cancer microenvironment via Stat3/IDO1/AhR axis to boost immunotherapy. Materials today. Bio, 37, 102924.

Yan X, et al. (2026) Activation of T Cell-Intrinsic p53 by Acetylation Elicits Antitumor Immunity to Boost Cancer Immunotherapy. Cancer discovery, 16(1), 155.

He L, et al. (2026) Oral Delivery of siSIRP α via Yeast-Derived β -Glucan Particles Enhances Macrophage-Mediated Antitumor Immunity by Blocking the CD47-SIRP α Axis. Journal of advanced research.

Qin J, et al. (2026) Electrode material and electrical delivery mode shape the mechanisms and efficacy of electrochemical tumor ablation. Bioelectrochemistry (Amsterdam, Netherlands), 171, 109301.

Yang T, et al. (2026) Covalent Inhibition of SHMT2 by Gambogic Acid Induces Ferroptosis Through Mitochondrial Collapse in Triple-Negative Breast Cancer. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(42), e20252.

Li J, et al. (2026) Effects of Different Chemical Modifications on the Polysaccharide Structure, Antioxidant, and Whitening Activities of Lavandula angustifolia Mill. Chemistry & biodiversity, 23(4), e71183.

Sun JW, et al. (2026) Synergistic Induction of Apoptosis by Apocytochrome C and Sodium Aescinate Is Mediated by Excessive Autophagy via the AKT-mTOR-TFEB Signaling Axis. *Cell biochemistry and function*, 44(4), e70214.

Yan H, et al. (2026) Autophagy-enhanced hybrid pyroptotic vesicles as personalized vaccines for cancer immunotherapy. *Journal of nanobiotechnology*, 24(1).

Qin J, et al. (2026) Spatially programmed Fe and Pt electrode-driven electrochemistry reconditions the tumor microenvironment and sensitizes triple-negative breast cancer to PD-1 Blockade. *Frontiers in oncology*, 16, 1819923.

Wu Y, et al. (2026) Stress-Induced ADGRL4 Orchestrates Tumor Progression and Metastasis by Inhibiting YAP1 Signaling and Activating Angiogenesis. *Cancer research*, 86(11), 2743.

Lubosch A, et al. (2025) The immune response against cancer is modulated by stromal cell fibronectin. *Neoplasia (New York, N.Y.)*, 67, 101196.

Rubio RM, et al. (2025) The transcription factor Helios restrains the anti-tumor capacity of CD8⁺ T cells. *Cell reports*, 44(12), 116680.

Wang F, et al. (2025) TSH Ligand-Based CAR-T Cell Effectively Eradicates TSHR-Positive Thyroid Cancer with Favorable Safety Profile. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, e13243.

Hadjigeorgiou AG, et al. (2025) Mathematical Modeling and Association Analysis Decipher the Impact of the Gut Microbiome on Cancer Immunotherapy. *Cancer research*, 85(16), 3139.

Li S, et al. (2025) Tumor Cell-Intrinsic Decr2 Regulates Ferroptosis and Immunotherapy Efficacy. *Cancer immunology research*, 13(8), 1284.

Fournier C, et al. (2025) Nanostructured lipid carriers based mRNA vaccine leads to a T cell-inflamed tumour microenvironment favourable for improving PD-1/PD-L1 blocking therapy and long-term immunity in a cold tumour model. *EBioMedicine*, 112, 105543.

Wei L, et al. (2025) Cancer cachexia-related monocytic myeloid-derived suppressor cells impair T-cell negative selection and predict immune-related adverse events. *Liver research (Beijing, China)*, 9(4), 298.

Huang X, et al. (2024) Neddylation signaling inactivation by tetracaine hydrochloride suppresses cell proliferation and alleviates vemurafenib-resistance of melanoma. *Cell biology and toxicology*, 40(1), 81.

Nueraihemaiti M, et al. (2024) The Anti-Vitiligo Effects of Feshurin In Vitro from *Ferula samarcandica* and the Mechanism of Action. *Pharmaceuticals (Basel, Switzerland)*, 17(9).

Hagiyaama M, et al. (2024) Efficient intracellular drug delivery by co-administration of two antibodies against cell adhesion molecule 1. *Journal of controlled release : official journal of the Controlled Release Society*, 371, 603.